Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQLE | Q14534 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.65 |
| ▸ | ICMT | O60725 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8425939 | 1.00 | SQLE (1.00) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL20449625 | 1.00 | SQLE (1.00) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| Trisnorsqualene Alcohol SCHEMBL2587282 | 1.00 | SQLE (1.00) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL16451625 | 1.00 | SQLE (1.00) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL5143580 | 0.92 | SQLE (0.96) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL24940711 | 0.89 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL16221426 | 0.89 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL24940909 | 0.89 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL8625008 | 0.89 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL24940873 | 0.89 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0521103-B1 | NOVEL CYCLOPROPYL SQUALENE DERIVATIVES AND THEIR USE AS INHIBITORS OF CHOLESTEROL SYNTHESIS | MERRELL DOW PHARMA (US) | 1995-09-27 | — | — | EP | claimed |
| EP-0596929-B1 | AMIDE DERIVATIVES OF ANTIBIOTIC A 40926 | LEPETIT SPA (IT) | 1995-07-26 | — | — | EP | claimed |
| US-8748414-B2 | Statin nanoparticles | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20110269830-A1 | STATIN NANOPARTICLES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-11-03 | — | — | US | disclosed |
| EP-0521103-B1 | NOVEL CYCLOPROPYL SQUALENE DERIVATIVES AND THEIR USE AS INHIBITORS OF CHOLESTEROL SYNTHESIS | MERRELL DOW PHARMA (US) | 1995-09-27 | — | — | EP | disclosed |
| EP-0521103-A4 | NOVEL CYCLOPROPYL SQUALENE DERIVATIVES AND THEIR USE AS INHIBITORS OF CHOLESTEROL SYNTHESIS | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0521103-A1 | NOVEL CYCLOPROPYL SQUALENE DERIVATIVES AND THEIR USE AS INHIBITORS OF CHOLESTEROL SYNTHESIS. | MERRELL DOW PHARMA (US) | 1993-01-07 | — | — | EP | disclosed |
| US-5102915-A | Cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-04-07 | — | — | US | disclosed |
| WO-1991014668-A1 | NOVEL CYCLOPROPYL SQUALENE DERIVATIVES AND THEIR USE AS INHIBITORS OF CHOLESTEROL SYNTHESIS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-03 | — | — | WO | disclosed |
| US-5051534-A | For treatment of vascular disease | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269830-A1 | STATIN NANOPARTICLES | HMGCR, PCSK9, CETP | SQLE 281/4885KMT2A 325/4885MAPT 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.